Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-When will a vaccine be ready? Here's a guess!

Wed, 13th May 2020 11:58

* European shares slump on virus fears

* Banks hit by earnings

* EZ industry output suffers record fall in March
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts Joice Alves (joice.alves@thomsonreuters.com) and
Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Stefano Rebaudo
(stefano.rebaudo@thomsonreuters.com) in Milan.

WHEN WILL A VACCINE BE READY? HERE'S A GUESS! (1050 GMT)

Assuming that countries in Europe aren't aiming at the so called "herd immunity", which
involves 60 to 90% of the population being infected by coronavirus, a vaccine could be the key
to return to a pre COVID-19 life.

A limited number of vaccine doses could be available before year end, says the European
pharma team at Credit Suisse.

With unlimited potential demand and governments controlling the vaccine distribution, supply
could jump to more than 1 billion doses by mid-2021.

The Swiss bank expects first safety data from human trials in the next few months from
Oxford/Astrazeneca, Sinovac and Novavax.

Once the vaccine is out there, for every 100 million doses CS sees a potential uplift to
2025 EPS of 2.6% for Sanofi, 2.3% for Astrazeneca and 1.1% GlaxoSmithKline.

The pharma team modelled sales/profits based on the current $5-6 billion flu vaccine market
where the average price per dose is $10 and over 200 million doses are produced annually.

(Stefano Rebaudo)

*****

CAUTIOUS AND SELECTIVE STOCKS RECOVERY LOOMING (0845 GMT)

The most likely scenario now is a cautious recovery in stock markets, as fears of a second
wave of infections will weigh at least for a while but huge stimulus programs already under way
will prop up share prices.

The latest rally was all about P/E ratio expansion after the ECB "opened the liquidity tap"
and the "markets internals are not risk-on" yet, Barclays says in a research note.

In this scenario the investment bank suggests "to use dips to add selectively to cyclicals,"
after downgrading Telecoms to underweight, while it is overweight on Tech, Mining, Cap Goods,
Healthcare and Utilities in defensives.

Barring the feared second wave of the virus, the economy will show signs of recovery and we
should not forget that "buying equities when PMIs bottom has been a typically better strategy
than buying when they are peaking."

If PMIs rebound and "history repeats itself, cyclicals should outperform".

(Stefano Rebaudo)

*****

OPENING SNAPSHOT: RISK-OFF MOOD HITS BANKS, VODAFONE UP (0737 GMT)

Risk-off mood gripped the financial markets on fresh fears about a second wave of the
coronavirus outbreak, while the gradual easing in lockdowns is under way.

Banks, and automotive sectors are the worst hit, down almost 3%. While utilities, retail and
telcos are standing their ground even if in negative territory.

ABN Amro is among the top losers in the Stoxx 600 index, down 7.1%, after a 395 million euro
loss, hit by loan provisions of 1.1 billion euros. Commerzbank shares down more than 3% after
posting a loss in Q1.

Arcelormittal under further pressure, after some target price cuts by investment banks. The
company recently announced an issue of shares and convertible notes worth $2 billion.

Agnelli's family holding company Exor is down 4.7% after French insurer Covea walked away
from its planned $9 billion purchase of the Bermuda-based reinsurer PartnerRe.

Vodafone shares in positive territory, as the company posted on Tuesday results in
line with expectations and said it would maintain its dividend.

(Stefano Rebaudo)

*****

NEGATIVE RATES, THE ULTIMATE FED 'PUT'? (0713 GMT)

There's nothing like the smell of negative interest in the morning to spice things up!

Powell's speech this afternoon (1300 GMT) will definitely be a key moment for the session
after Trump pressured the Fed to look into "the gift" of negative rates.

"I am looking at that bounce back in US e-minis, and once again, investors are counting on
Fed Chair Powell to grease the wheels off yet another equity markets recovery rally", writes
AxiCorp strategist Stephen Innes, pointing out to positive Wall Street futures currently
outperforming European bourses in the red.

"All that policy deluge before even thinking about negative rates, which is arguably their
ace in the hole for more rainy days, has got investors lining up for their rally bus tickets
again", he commented.

This could of course very well also end up in a case of 'buy the rumour, sell the news' if
Powell brushes off the idea of going subzero.

"The central banker might use the opportunity to nip the negative rates chatter in the bud",
warned at CMC Markets analyst David Madden.

Anyhow, we still got a few hours to wait so let's take a look at the last 20 years of the 10
year U.S. benchmark and see if we can see a trend about where it's heading:

(Julien Ponthus)

*****

ON THE RADAR: L'OREAL, BANKS, ASTON MARTIN AND VOLVO (0635 GMT)

European bourses are coming under renewed selling pressure as fears of a new wave of
infections are gripping financial markets.

On the corporate front, L'Oreal decided to give up on share buyback programmes in
2020 and on a planned 10.4% dividend increase, but to stick to the same 2019 payout per share of
3.80 euros.

More banks are swinging to the red in the first quarter. Commerzbank posted a worse than
expected net loss of 295 million euros, as the lender undergoes a restructuring due to the
coronavirus outbreak. Commerzbank shares are down 2.3% in early trade.

Ducth bank ABN Amro reported a 395 million euro loss, hit by loan provisions of 1.1 billion
euros. Meantime, Deutsche Bank top managers will waive one month of fixed pay, in an effort to
cut costs; shares are down 2% in early trade.

The travel and leisure industry stays on the radar as TUI said it needed to cut
its fixed cost base by 30% and thousands of jobs as it looks to right-size its business to
survive.

Car makers Aston Martin posted a first-quarter pretax loss of 119 million pound,
after sales dropped by nearly a third, while Volvo ditched dividend payment.

Moller-Maersk first-quarter revenue were in line with expectations, but the company warned
about a drop of as much as 25% in global container volumes in the second quarter.

Alstom is sticking to the terms of its previously agreed deal to buy the rail
division of Canada's Bombardier for up to 6.2 billion euros.

But another acquisition falls through with Exor saying it will retain control of
Bermuda-based reinsurer ParnerRe after Covea walked away from the $9 billion deal acquisition.

Eiffage first-quarter construction revenue slumped 13.0%.

Salvatore Ferragamo, whose core profits plunged by 82.2% to 12 million euros in the three
months to March said it could not provide guidance on expected sales for 2020.

(Stefano Rebaudo)

*****

MORNING CALL: IN THE RED ON RENEWED CORONAVIRUS FEARS (0636)

European futures are in the red amid fears of a fresh spike in coronavirus cases and renewed
U.S.-China tensions.

Wall Street's fall overnight seems set to hit a fragile European market, which has recently
swung between optimism over some easing in lockdowns and anxiety about a second wave of
infections.

U.S. markets sentiment soured after U.S. infectious disease expert Anthony Fauci warned that
a premature lifting of social distancing measures could lead to additional outbreaks.

Fresh trade war fears also emerged when a leading U.S. Republican senator proposed
legislation that would authorize Trump to impose sanctions on China if it fails to give a full
account of events leading to the outbreak.

(Stefano Rebaudo)

*****

(Reporting by Joice Alves, Julien Ponthus and Stefano Rebaudo)

More News
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more
19 Feb 2024 15:59

London close: Stocks manage gains on globally quiet day

(Sharecast News) - London's financial markets finished in positive territory on Monday, with stocks closing in the green after overcoming minor losses earlier in the session.

Read more
19 Feb 2024 15:39

UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax

(Alliance News) - AstraZeneca PLC on Monday said it has completed the acquisition of Icosavax Inc.

Read more
19 Feb 2024 11:51

LONDON MARKET MIDDAY: Stocks lack direction amid quiet start to week

(Alliance News) - Stock prices in London lacked direction at midday Monday, amid a quiet start to the week.

Read more
19 Feb 2024 08:44

LONDON MARKET OPEN: Stocks drift; Currys surges on takeover interest

(Alliance News) - Stock prices in London were looking for direction early Monday, as investors weighed possible trajectories for US interest rate cuts and a China's economic recovery.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.